LimmaTech sets up as de facto GSK vaccine R&D unit in wake of $190M buyout

Nick Paul Taylor LimmaTech Biologics, a spillover from the $ 190 million (€169 million) takeover of GlycoVaxyn by GlaxoSmithKline, has opened its doors. The biotech is starting ...

Trial set for Pfizer in Protonix Medicaid rebate case it inherited

Eric Palmer A federal judge's inclination means Pfizer could remain in the line of fire to pay out more than $ 2 billion. That is the potential liability Pfizer faces for a federal ...

UPDATED: Novo to spend $1.2B, hire 700 for its first major drug plant in U.S.

Eric Palmer With a game-changing oral diabetes treatment moving through clinical trials, Novo Nordisk will spend about $ 2 billion on its first API plant in the U.S., ...

Avalanche hits the brakes on its gene therapy program after a Phase II misstep

Damian Garde Avalanche Biotechnologies, months removed from a costly Phase II dud, is calling off plans for further study of its lead gene therapy candidate, heading back to the lab ...

Roche dumps its cancer drug R&D pact with Wilex

John Carroll Roche is bowing out of a two-year-old collaboration with a subsidiary of a struggling Wilex. FierceBiotech News

With new cash on its way, it’s back to buying for deal-happy Allergan, CEO says

Carly Helfand On Monday, Allergan agreed to sell off a $ 40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries. ...

Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast

Eric Palmer The speed bump that sales of Biogen's Tecfidera hit earlier this year, slowing its growth, has turned into a big old pothole and it has shaken investors pretty hard ...

Novartis’ newly acquired melanoma combo wins EU recommendation

Carly Helfand Novartis' recently acquired melanoma duo, Tafinlar and Mekinist, has won a recommendation from the European Medicines Agency's Committee for Medicinal Products ...

DOJ criminal probe takes a look at trade associations

Eric Palmer For more than a year, the Justice Department (DOJ) has been pursuing a criminal investigation into the possibility of pricing collusion among makers of generics. Three companies ...

FierceBiotech Radio on big approvals for Novartis and Vertex, Mylan’s real estate controversy, and @brentlsaunders

Alok Saboo FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including Novartis and Vertex Pharmaceuticals scoring ...

Nurse pleads guilty to taking Insys kickbacks as Subsys marketing probe continues

Tracy Staton In an apparent sign that federal prosecutors are zeroing in on the pain-drug maker Insys Therapeutics, a Connecticut nurse and top prescriber has pleaded guilty to accepting ...

Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares

John Carroll Three months after retrieving rights to the lymphoma drug EPZ-6438 from Eisai in a $ 110 million deal, Epizyme has posted a positive glimpse at the drug's efficacy ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS